Zolbetuximab  (Synonyms: IMAB362)

Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors^[1].

Zolbetuximab (0-100 μg/mL) binds to CLDN18.2⁺ PC cells, and induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models^[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1496553-00-4

Liquid

Colorless to light yellow

[Zolbetuximab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.  [Content Brief]

  [2]. Türeci Ӧ, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096.  [Content Brief]

  [3]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424.  [Content Brief]